RxDoctor Payments Data

Jo Bonner

St. Louis, MONPI 1982701371

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 29.9% of the total. Reporting peaked in 2019 at $550 and has fallen 80.9% since, to $105 in 2023.

$974in general payments, 2019–2025

Across 45 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$291
  • Amgen$245
  • Lundbeck LLC$137
  • Supernus Pharmaceuticals, Inc.$105
  • Lilly USA, LLC$90
  • Teva Pharmaceuticals USA, Inc.$35
  • plus $71 from 3 others
$527,323in research payments, 2019–2025

Across 96 payments — averaging $5492.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$342K
  • Novartis$100K
  • Eli Lilly$37K
  • Teva Pharmaceuticals USA, Inc.$36K
  • Alkermes, Inc.$5K
  • Boehringer Ingelheim$4K
  • plus $3K from 1 others

What the payments were for

  • Speaking & faculty fees$232%
  • Food & beverage$95198%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →